Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05309265 | Vocational Rehabilitation for the Return to Work of Breast Cancer Patients: a Feasibility Study(VocRehab) | active not recruiting | N/A | 16 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | May 7, 2026 | clinicaltrials |
| NCT05315154 | Sentinel Lymph Node Biopsy Versus no Axillary Surgery in Early Breast Cancer(VENUS) | active not recruiting | N/A | 800 | University of Campinas, BrazilOTHER | 1 |
| May 7, 2026 |
| clinicaltrials |
| NCT05596409 | ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study(ELCIN) | active not recruiting | Phase 2 | 61 | Stemline Therapeutics, Inc.INDUSTRY | 6 | May 7, 2026 | clinicaltrials |
| NCT02488967 | Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer | active not recruiting | Phase 3 | 782 | NRG OncologyOTHER | 2 | May 6, 2026 | clinicaltrials |
| NCT02918084 | CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer(GIM10-CONSENT) | active not recruiting | Phase 3 | 1,000 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, ItalyOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04553133 | PF-07104091 as a Single Agent and in Combination Therapy | active not recruiting | Phase 2 | 157 | PfizerINDUSTRY | 4 | May 6, 2026 | clinicaltrials |
| NCT04647916 | Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases | active not recruiting | Phase 2 | 44 | SWOG Cancer Research NetworkNETWORK | 1 | May 6, 2026 | clinicaltrials |
| NCT04849871 | Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma(BreaStBRT) | active not recruiting | N/A | 134 | Washington University School of MedicineOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05591547 | Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen(APBI RISE) | active not recruiting | Phase 2 | 91 | Sanford HealthOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06125522 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) | active not recruiting | Phase 1 / Phase 2 | 11 | PfizerINDUSTRY | 4 | May 6, 2026 | clinicaltrials |
| NCT01202851 | Relaxation for Women With Breast Cancer Undergoing Radiotherapy | active not recruiting | Phase 3 | 681 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03607552 | Non-contrast DWI for Supplemental Screening | active not recruiting | — | 269 | University of WashingtonOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT01245712 | Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer | active not recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT02466737 | Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery(INSEMA) | active not recruiting | N/A | 5,505 | University of RostockOTHER | 2 | May 1, 2026 | clinicaltrials |
| NCT05143229 | Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer(ASSET) | active not recruiting | Phase 1 | 18 | University of Kansas Medical CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT00433420 | Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer | active not recruiting | Phase 3 | 2,000 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, ItalyOTHER | 0 | Apr 30, 2026 | clinicaltrials |
| NCT04467411 | The EMBRACE Study The EMBRACE Study(EMBRACE) | active not recruiting | — | 70 | University of AberdeenOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05645471 | Together After Cancer | active not recruiting | N/A | 480 | University of South FloridaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06172127 | PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer(DEMETHER) | active not recruiting | Phase 2 | 165 | MedSIROTHER | 5 | Apr 29, 2026 | clinicaltrials |
| NCT06628388 | Nurse-led Primary Healthcare Intervention Model in Women's Health Management in Hong Kong(JCDATAZONEWH) | active not recruiting | N/A | 1,728 | The University of Hong KongOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07555639 | An Integrated Genomic Approach to Assess Genetic Risk and Drug Sensitivity(GERSOM) | active not recruiting | N/A | 4,000 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07556900 | Exploring the Potential of Artificial Intelligence for Earlier Breast Cancer Detection: A Retrospective Multi-Reader Study Based on AI-Assisted Mammographic Interpretation (EARLIEST-AI)(EARLIEST-AI) | active not recruiting | — | 785 | Mammograaf RadioloogiakliinikOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT01905046 | Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer | active not recruiting | Phase 3 | 86 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03789110 | NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer | active not recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05509751 | The SOAR Study: a Study of Geriatric Assessment and Exercise for Older Adults and Their Support Person(SOAR) | active not recruiting | N/A | 60 | Martine PutsOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05645380 | Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC(NeoTRACT) | active not recruiting | Phase 2 | 139 | University of Kansas Medical CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05705401 | Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer(HERO) | active not recruiting | Phase 3 | 1,300 | NRG OncologyOTHER | 2 | Apr 27, 2026 | clinicaltrials |
| NCT01382082 | Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy(CANTAB) | active not recruiting | — | 1,432 | University of Rochester NCORP Research BaseOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT01517945 | Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study | active not recruiting | — | 252 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT02734290 | Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 29 | Providence Health & ServicesOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03155997 | Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer(monarchE) | active not recruiting | Phase 3 | 5,637 | Eli Lilly and CompanyINDUSTRY | 38 | Apr 24, 2026 | clinicaltrials |
| NCT04373031 | Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer | active not recruiting | Phase 2 | 12 | Providence Health & ServicesOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05508984 | Clinical Outcomes and Patient Satisfaction With Use of the Amma System | active not recruiting | — | 15 | Providence Health & ServicesOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05797545 | Comparison of Ultrasound and Breast MRI for Breast Cancer Detection | active not recruiting | N/A | 1,756 | Samsung Medical CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03756298 | Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | active not recruiting | Phase 2 | 284 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06062810 | Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms(Drugs-SNPs) | active not recruiting | Phase 2 / Phase 3 | 600 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04595565 | Sacituzumab Govitecan in Primary HER2-negative Breast Cancer(SASCIA) | active not recruiting | Phase 3 | 1,332 | GBG Forschungs GmbHOTHER | 7 | Apr 22, 2026 | clinicaltrials |
| NCT04837820 | The Effect of Acupuncture on Cancer-Related Cognitive Difficulties | active not recruiting | Phase 2 | 270 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06215469 | Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads) | active not recruiting | N/A | 40 | University of California, San FranciscoOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT02204098 | Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy | active not recruiting | Phase 1 | 27 | Washington University School of MedicineOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT02744053 | DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer | active not recruiting | Early Phase 1 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT03927027 | Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection | active not recruiting | Phase 3 | 534 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT03961685 | Cancer Activity and Lifestyle Measurement Study(CALM) | active not recruiting | — | 14 | Ohio State UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT06187103 | Evaluation of Improved Onboard Patient Imaging | active not recruiting | — | 40 | Varian, a Siemens Healthineers CompanyINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07541703 | Independent, External, Blinded Retrospective Validation of an AI-based Prognostic Assay in ER-Positive/HER2-Negative Early Breast Cancer | active not recruiting | — | 2,200 | Spotlight MedicalINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT03366844 | Breast Cancer Study of Preoperative Pembrolizumab + Radiation | active not recruiting | Phase 1 / Phase 2 | 66 | Stephen ShiaoOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03820141 | Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer(DTP) | active not recruiting | Phase 2 | 51 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06443359 | Hypofractionated Regional Nodal Irradiation in Breast Cancer | active not recruiting | N/A | 56 | Corewell Health EastOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02326974 | T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA | active not recruiting | Phase 2 | 164 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02917421 | Accelerated Radiation Therapy (ART) to the Breast and Nodal Stations(ART) | active not recruiting | Phase 1 / Phase 2 | 88 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 7, 2026source: clinicaltrials